Clearside Biomedical logo

Clearside BiomedicalNASDAQ: CLSD

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

02 June 2016

Next earnings report:

13 November 2024

Last dividends:

N/A

Next dividends:

N/A
$76.98 M
-76%vs. 3y high
40%vs. sector
-vs. 3y high
-vs. sector
-107%vs. 3y high
8%vs. sector
-89%vs. 3y high
75%vs. sector

Price

after hours | Fri, 01 Nov 2024 23:30:59 GMT
$1.03+$0.03(+3.51%)

Dividend

No data over the past 3 years
$90.00 K$120.00 K
$90.00 K-$7.59 M

Analysts recommendations

Institutional Ownership

CLSD Latest News

Clearside Biomedical Appoints Tony Gibney as New Chair of the Board of Directors
globenewswire.com04 November 2024 Sentiment: -

ALPHARETTA, Ga., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today the appointment of Tony Gibney as Chair of its Board of Directors, effective November 1, 2024. Mr. Gibney, who joined Clearside's Board as an independent director in April 2024, succeeds Clay Thorp, who will continue serving as a member of the Board.

Clearside Biomedical to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Tuesday, November 12, 2024
globenewswire.com31 October 2024 Sentiment: POSITIVE

ALPHARETTA, Ga., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its third quarter 2024 financial results will be reported on Tuesday, November 12, 2024 after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.

After Plunging -15.7% in 4 Weeks, Here's Why the Trend Might Reverse for Clearside Biomedical (CLSD)
zacks.com15 August 2024 Sentiment: POSITIVE

Clearside Biomedical (CLSD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Clearside Biomedical, Inc. (CLSD) Reports Q2 Loss, Lags Revenue Estimates
zacks.com12 August 2024 Sentiment: NEUTRAL

Clearside Biomedical, Inc. (CLSD) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.15 per share a year ago.

Clearside Biomedical to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
globenewswire.com08 August 2024 Sentiment: POSITIVE

ALPHARETTA, Ga., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced that management will present a corporate update at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference which will be available on demand on Thursday, August 15, 2024, at 7:00 a.m. ET. Victor Chong, MD, MBA, Chief Medical Officer, will also participate in a panel discussion on the Evolving Therapeutic Landscape of AMD.

Clearside Biomedical, Inc. (CLSD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
zacks.com05 August 2024 Sentiment: POSITIVE

Clearside Biomedical (CLSD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Clearside Biomedical, Inc. (CLSD) Suprachoroidal Space Drug Delivery (Transcript)
seekingalpha.com24 July 2024 Sentiment: NEUTRAL

Clearside Biomedical, Inc. (NASDAQ:CLSD ) Suprachoroidal Space Drug Delivery Call July 24, 2024 8:00 AM ET Company Participants Jenny Kobin - Investor Relations George Lasezkay - President and Chief Executive Officer Glenn Yiu - Scientific Advisory Board Victor Chong - Chief Medical Officer David Brown - Director of Research, Retina Consultants Houston Conference Call Participants Annabel Samimy - Stifel Andreas Argyrides - Oppenheimer & Co. Serge Belanger - Needham & Company Yi Chen - H.C. Wainwright Operator Greetings, and welcome to the Clearside Biomedical KOL Webinar.

Clearside Biomedical Appoints Dr. Glenn Yiu to its Scientific Advisory Board
globenewswire.com11 July 2024 Sentiment: POSITIVE

ALPHARETTA, Ga., July 11, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today the appointment of Glenn C. Yiu, M.D., Ph.D., Professor of Ophthalmology at the University of California, Davis, to its Scientific Advisory Board (SAB), which is comprised of industry-leading retinal physicians who provide medical and scientific expertise and input on the Company's research and development programs.

Why Is Clearside Biomedical Stock Gaining Today?
benzinga.com25 June 2024 Sentiment: POSITIVE

Oppenheimer initiated coverage on Clearside Biomedical Inc CLSD, a biopharmaceutical company focused on delivering therapies to the back of the eye through the suprachoroidal (SCS) space.

Clearside Biomedical to Report First Quarter 2024 Financial Results and Provide Corporate Update on Thursday, May 9, 2024
GlobeNewsWire30 April 2024 Sentiment: POSITIVE

ALPHARETTA, Ga., April 30, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company transforming the way treatments are delivered to the back of the eye using the suprachoroidal space (SCS®), announced today that it will release its financial results for the first quarter of 2024 on Thursday, May 9, 2024 after the markets close. A webcast and conference call will be held by management at 4:30 p.m. Eastern Time to discuss the results and provide an update on the company.

What type of business is Clearside Biomedical?

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

What sector is Clearside Biomedical in?

Clearside Biomedical is in the Healthcare sector

What industry is Clearside Biomedical in?

Clearside Biomedical is in the Biotechnology industry

What country is Clearside Biomedical from?

Clearside Biomedical is headquartered in United States

When did Clearside Biomedical go public?

Clearside Biomedical initial public offering (IPO) was on 02 June 2016

What is Clearside Biomedical website?

https://clearsidebio.com

Is Clearside Biomedical in the S&P 500?

No, Clearside Biomedical is not included in the S&P 500 index

Is Clearside Biomedical in the NASDAQ 100?

No, Clearside Biomedical is not included in the NASDAQ 100 index

Is Clearside Biomedical in the Dow Jones?

No, Clearside Biomedical is not included in the Dow Jones index

When was Clearside Biomedical the previous earnings report?

No data

When does Clearside Biomedical earnings report?

The next expected earnings date for Clearside Biomedical is 13 November 2024